Search | Clinical Trials Finder

Conditions: Electronic Cigarette Related Lung Damage
Interventions: Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT; Drug · Diagnostic Test
Lead sponsor: Y. Michael Shim, MD; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Interstitial Lung Disease
Interventions: [68Ga]CBP8, Dotarem; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: SUPPORT-T Educational Intervention; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Fibrosis Lung, Systemic Sclerosis
Interventions: Bronchoscopy with lavage; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions: Double Lung Transplantation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Thoracic Diseases, Lung Cancer, Lung Transplant
Interventions: Tissue Banking; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Interstitial Lung Disease, Connective Tissue Diseases
Interventions: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs); Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: ILD
Interventions: Xenon-129; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 21 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoidosis, Pulmonary Arterial Hypertension
Interventions: Iloprost; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Interstitial Lung Disease
Interventions: Trans Sodium Crocetinate, Placebo; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Systemic Sclerosis
Interventions: Pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more

Conditions: Lung Diseases, Interstitial
Interventions: OFEV; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Tucson, Arizona • Chesterfield, Missouri • Kalispell, Montana + 3 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Belumosudil, BSC; Drug · Other
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more

Conditions: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label); Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more

Conditions: Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions: [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging; Drug · Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease
Interventions: Not listed
Lead sponsor: St. Lawrence Health System; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Potsdam, New York

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions: Placebo, LAM-001; Drug
Lead sponsor: OrphAI Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Conditions: Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
Interventions: Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions: Pirfenidone; Drug
Lead sponsor: Jesse Roman; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Riverside, California + 29 more

Conditions: Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions: Treprostinil; Drug
Lead sponsor: Rajan Saggar; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

Thoracic Specimen Registry

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Lung Disease Associated With Rheumatoid Arthritis

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension